Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Study of Lenalidomide and Dexamethasone with or without Pembrolizumab in Newly Diagnosed and Treatment-Naïve Multiple Myeloma
Compare the Progression Free Survival (PFS) as assessed by independent central review according to the International Myeloma Working Group response criteria, (IMWG criteria) between treatment arms.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
A Study in Healthy Infants of the Safety, Tolerability, and Immunogenicity of Haemophilus influenzae, Type b/Hepatitis B Vaccine Manufactured With a Modified Process
Main objective : (1a) To demonstrate that at 1 month after the third dose of vaccine, both the modified process vaccine and COMVAX™ will induce adequate seroprotection rates (SPR, % of subjects with...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Merck-Serono
Update Il y a 4 ans
MERCK SERONO 28062 : Essai de phase 1 visant à déterminer la dose maximale tolérée de 2 schémas d'administration d'un inhibiteur de MEK (AS703026), chez des patients ayant une tumeur solide. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A multicenter, open label, phase I trial of the MEK inhibitor AS703026 given orally to subjects with solid tumours
Country
France
organs
Tumeurs solides
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Merck Serono S.A. - Geneva
Update Il y a 4 ans
A Phase IV multicentre, randomised, double-blind, placebo controlled, trial to evaluate the safety and efficacy of Raptiva ® in the treatment of subjects with moderate to severe plaque psoriasis involving hands and/or feet, with or without pustules
To evaluate the safety and efficacy of Raptiva ® against placebo to control chronic moderate to severe plaque-type psoriasis involving hands and/or feet scoring PGA (PGA - H&F) ≥3 in subjects not suit...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancer
-Evaluate PFS per RECIST 1.1 by blinded independent radiologists’ review of all subjects with recurrent/progressive metastatic urothelial cancer treated with pembrolizumab (MK-3475) compared to paclit...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
Early Access of MK-0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options
This program is designed to provide expanded access to MK-0518 prior to the product’s approval and availability on the market. The safety and tolerability of MK-0518 400 mg b.i.d. for the treatment o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Phase IIa Open Label, Randomized Clinical Trial to Study Vintafolide and Paclitaxel in Subjects with Advanced Triple Negative Breast Cancer Using SPECT/CT scan with Etarfolatide (EC20) for Subject Selection Ensayo clínico de fase IIa abierto y aleatorizado para estudiar Vintafolide y paclitaxel en pacientes con cáncer de mama triplemente negativo avanzado, con selección de pacientes mediante etarfolatide (EC20)
To evaluate the progression-free survival of vintafolide monotherapy relative to paclitaxel and the progression-free survival of vintafolide + paclitaxel combination therapy relative to paclitaxel in...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
Study of CANCIDAS in Children types of ungal infections
The main objectives of this study are to evaluate the safety, tolerability, and efficacy of caspofungin therapy, administered as 50 mg/m2 IV once daily (maximum 70 mg/day) following a loading dose of ...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Merck, sharp & Dohme (Human Health) Ltd
Update Il y a 4 ans
A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Therapy
After 6 weeks of treatment, to assess the effect of the addition of MK 0941 compared with the addition of glimepiride on 24-hour weighted mean glucose (24-hour WMG).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Merck-Serono
Update Il y a 4 ans
Merck START : Essai de phase 3 randomisé visant à déterminer si le vaccin anticancéreux Stimuvax® est efficace pour prolonger la vie, chez des patients ayant un cancer du poumon non à petites cellules de stade III non résécable. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de déterminer si le vaccin anticancéreux Stimuvax® est efficace pour prolonger la durée de vie des patients ayant un cancer du poumon non à petites cellules non opérable. ...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai clos aux inclusions
More information
Previous
8
9
10
11
12
13
14
15
16
17
Next